Anebulo Pharmaceuticals, Inc.
ANEB
$2.27
-$0.06-2.58%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.45M | 1.20M | 1.25M | 1.37M | 1.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.26M | 2.33M | 1.89M | 2.59M | 2.41M |
| Operating Income | -2.26M | -2.33M | -1.89M | -2.59M | -2.41M |
| Income Before Tax | -2.16M | -2.14M | -1.68M | -2.46M | -2.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.16M | -2.14M | -1.68M | -2.46M | -2.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.16M | -2.14M | -1.68M | -2.46M | -2.20M |
| EBIT | -2.26M | -2.33M | -1.89M | -2.59M | -2.41M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.05 | -0.05 | -0.04 | -0.09 | -0.08 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.06 | -0.05 |
| EPS Diluted | -0.05 | -0.05 | -0.04 | -0.09 | -0.08 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.06 | -0.05 |
| Average Basic Shares Outstanding | 41.08M | 41.08M | 41.08M | 27.42M | 25.93M |
| Average Diluted Shares Outstanding | 41.08M | 41.08M | 41.08M | 27.42M | 25.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |